Clinical Risk Assessment
INRstar Anticoagulation Decision Support Software
Residual Risks ‘As Far as Possible’ (AFAP)
Anticoagulation is an inherently risky process. It offers measurable benefits to patients in the reduction of the risk of thromboembolic events and in the treatment of established thrombotic episodes but, inevitably, it increases the risk of bleeding episodes. It is the aim of INRstar to reduce the risks and increase the benefits as far as possible.
To meet these aims INRstar undergoes a process of full Clinical Risk Assessment at all stages of its design, development and deployment. Standard approved risk assessment methods are used and risks quantified using an appropriate risk matrix.(see Appendix 1 in the PDF available from the link below.)
Measures are implemented to reduce all identified clinical risks to an acceptable level but there are certain risks which it is not possible to fully mitigate. These residual risks are classified as AFAP risks (As far as possible).
This document outlines the clinical risks assessed as AFAP within INRstar.
Click on 'Additional Files' to download the Clinical Risk Assessment PDF.
Users should be aware of these residual risks and should be particularly careful when performing actions which contain them.
You will need Acrobat Reader to open this file, if you do not have it please click this link to download it http://get.adobe.com/uk/reader/